Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64290532 | 6429053 | 2 | F | 20070524 | 0 | 20070823 | 20120424 | PER | PHEH2007US08778 | NOVARTIS | 85.00 | YR | M | N | 0.00000 | 20090702 | CN | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64290532 | 6429053 | 1 | PS | LOTENSIN | 1 | ORAL | ORAL | U | U | 19851 | |||||||||
| 64290532 | 6429053 | 2 | SS | FLOMAX | 1 | ORAL | 0.4 MG, QD, ORAL | U | U | 0 | |||||||||
| 64290532 | 6429053 | 3 | SS | HYDROCHLOROTHIAZIDE | 1 | ORAL | ORAL | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 64290532 | 6429053 | 2 | BENIGN PROSTATIC HYPERPLASIA |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 64290532 | 6429053 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 64290532 | 6429053 | BENIGN PROSTATIC HYPERPLASIA | |
| 64290532 | 6429053 | FALL | |
| 64290532 | 6429053 | SYNCOPE |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 64290532 | 6429053 | CSM |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 64290532 | 6429053 | 2 | 20070424 | 20070524 | 0 |